



Centre Name: CANCER CENTRE OF SOUTHEASTERN ONTARIO AT KINGSTON GENERAL HOSPITAL	
Reporting Date (month/yr): March 31, 2009	Updated By: Tracie Hanna

Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
MISCELLANEOUS TRIALS				
ACCRN07	Protocol For The Enrollment On The Official COG Registry, The Childhood Cancer Research Network (CCRN)	CCRN	Dr. M. Silva X3834	R
ALTE03N1	Key Adverse Events after Childhood Cancer (All ages however diagnosis must have been before Age 21 yrs) http://www.clinicaltrials.gov/ct/show/NCT00082745?order=1	COG	Dr. M. Silva X3834	R
ADVL0525	A Phase II Study of Pemetrexed in Children with Recurrent Malignancies (Ages: up to 21 yrs) http://www.clinicaltrials.gov/ct/show/NCT00459147?term=ADVL0525&rank=1	COG	Dr. M. Silva X3834	O
AREN0532	Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor (Ages 0-29 yrs) http://www.clinicaltrials.gov/ct/show/NCT00352534?order=1	COG	Dr. M. Sliva X3834	R
AREN0533	Treatment of Newly Diagnosed Higher Risk Favourable Histology Wilms Tumours (Ages: up to 29 yrs) http://www.clinicaltrials.gov/ct/show/NCT00379340?order=1	COG	Dr. M. Sliva X3834	O
ABTR01B1	A COG Protocol for Collecting and Banking Paediatric Research Specimens Including Rare Pediatric Tumours (Ages ≥ 18yrs) Link not available	COG	Dr. M. Silva X3834	R

Status Key:				
R - Recruiting	P - Pending	O - On Hold	C - Closed on Site	X - Closed by Sponsor
NR - New Recruiting	NP - New Pending			



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
AGCT0132	A Phase III Study of Reduced Therapy on the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumours (Ages 0-21 yrs) http://www.clinicaltrials.gov/ct/show/NCT00053352?order=1	COG	Dr. M. Silva X3834	R
CRHTBS	Clinical Hypersensitivity to Radiotherapy: Tissue Banking and Analysis of the Underlying Molecular Mechanisms (Ages ≥18 yrs) Link not available at this time	CARO	Dr. C. Falkson X6736	R
ARRAY-380-101	A Phase I, Open-label, Multiple Dose Study to Assess the Safety, Tolerability and pHarmacokinetics of ARRY-380 Given on a Daily Oral Regimen in Subjects With Advanced Cancer (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct2/show/NCT00650572?term=array-380&rank=1	Array Biopharmaceuti cals	Dr. T. Baetz X 4415	R
SC20	A phase III international randomized trial of single versus multiple fractions for re-irradiation of painful bone metastases (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00080912?order=1	NCIC CTG	Dr. C. DeMetz X6736	R
PROOF	PROtecting Ovaries and Fertility During Chemotherapy; A Randomized Controlled Trial of Gonadotropin Releasing Hormone Agonist for Fertility Preservation in Oncology Patients (Ages 18-38 yrs) http://www.clinicaltrials.gov/ct/show/NCT00380406?order=1	OHRI-CIHR	Dr. T. Baetz X 4415	R

BREAST TRIALS

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
WO20697	A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab versus pertuzumab and docetaxel in patients with locally advanced, inflammatory or early stage HER2 positive breast cancer Link not available yet	ROCHE	Dr. Y. Madarnas X4184	R
BO20289 (Beatrice)	An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer. http://www.clinicaltrials.gov/ct2/show/NCT00528567?term=BO20289&rank=1	Roche	Dr. Y. Madarnas xNA	R
B42	A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer (Ages: Postmenopausal) http://www.clinicaltrials.gov/ct/show/NCT00382070?order=1	NSABP	Dr. W. Lofters X4184	R
MA17R	A double blind re-randomization to Letrozole or placebo for women completing five years of adjuvant Letrozole in the MA.17 study (Ages ≥18 yrs) http://www.ctg.queensu.ca/public/Clinical_Trials/public_ph_3_trial_summary.html#MA17R	NCIC CTG	Dr. W. Shelley X6611	R
AROW	Accelerated Radiotherapy Outcomes in Women (AROW) (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00156130?order=1	OCOG	Dr. W. Shelley X4184	R

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
MAP3	A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer (Ages ≥ 35 yrs; postmenopausal) http://www.clinicaltrials.gov/ct/show/NCT00083174?order=1	NCIC CTG	Dr. C. Falkson X4184	R
E7389-G000-301	A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes and Refractory to the Most Recent Chemotherapy (Ages ≥ 18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00337103?order=1	EISAI	Dr. W. Lofters x4184	R
LUNG TRIALS				
TORCH	An International Multicentre Randomized Phase III Study of First-line Erlotinib Followed by Second-Line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer (Ages > 18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00349219?order=1	Ozmosis Research/NCI Naples	Dr. R. Gregg X NA	R

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
OSI-774-302	A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non small Cell Lung Carcinoma who have EGFR-Positive Tumors (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00373425?order=1	OSI Pharmaceutical	Dr. R. Gregg x6611	C
A6181087	A Multicenter, Randomized, Double-Blind, Controlled Phase 3 , Efficacy and Safety Study of Erlotinib with or Without Sunitinib (SU011248) in the Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00457392?order=1	Pfizer	Dr. R. Gregg X 6611	R
GASTROINTESTINAL (GI) TRIALS				
CRC.2	A Randomized Phase III Trial of Oxaliplatin Plus 5-Fluouracil (5-FU)/Leucovorin with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00079274?order=1 This trial has been suspended temporarily	NCIC CTG	Dr. W. Lofters X 6736	O
PHL-050	A Phase II Study of VEGF Trap in Patients with Previously Treated Metastatic Colorectal Cancer (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00407654?order=1	PMH pII	Dr. A. Tomiak X 6736	C/X

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
PET CAM	The Impact of Positron Emission Tomography (PET) Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases: A Prospective, Multicentre Randomized Clinical Trial (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00265356?order=6	OCOG	Dr. D. Jalink x6736	R
R-04	A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00058474?order=1	NSABP	Dr. C. Falkson X6736	R
ES2	A Randomized Phase III Study in Advanced Oesophageal Cancer To Compare Palliation of Dysphagia In Patients Treated With Radiotherapy Versus Chemo-Radiotherapy (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00193882?order=1	NCIC CTG	Dr. J. Biagi X6611	R
GAC1	Phase III trial of adjuvant chemoradiation after resection of gastric or gastroesophageal adenocarcinoma (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00052910?order=1	NCIC CTG	Dr. J. Biagi X6736	R

GENITOURINARY (GU) TRIALS

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
HIS-0611-0602	OPEN-LABEL, MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF MCC IN THE TREATMENT OF PATIENTS WITH NON-MUSCLE INVASIVE (SUPERFICIAL) BLADDER CANCER AT HIGH RISK OF PROGRESSION AND WHO ARE REFRACTORY TO BCG HTTP://WWW.CLINICALTRIALS.GOV/CT2/SHOW/NCT00406068?TERM=MCC+BIONICHE&RANK=1	Bioniche Life Sciences Inc.	613-548-6033	R
SPI-612	A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 3 TRIAL OF SINGLE-DOSE INTRAVESICAL EOQUIN® AS A SURGICAL ADJUVANT INSTILLED IN THE EARLY POSTOPERATIVE PERIOD IN PATIENTS UNDERGOING TRANSURETHRAL RESECTION FOR NONINVASIVE BLADDER CANCER HTTP://WWW.CLINICALTRIALS.GOV/CT2/SHOW/NCT00598806?TERM=SPI-612+EOQUIN&RANK=1	Spectrum Pharmaceuticals	613-548-6033	R
D4200L00010	A RANDOMIZED, DOUBLE-BLIND, MULTICENTRE, PHASE II CONTROLLED TRIAL ASSESSING ZACTIMATM (VANDETANIB) AGAINST PLACEBO IN PROLONGING THE OFF-TREATMENT INTERVAL IN PROSTATE CANCER SUBJECTS UNDERGOING INTERMITTENT ANDROGEN DEPRIVATION HORMONAL THERAPY HTTP://WWW.CLINICALTRIALS.GOV/CT2/SHOW/NCT00686036?TERM=D4200L00010&RANK=1	Astra Zeneca/CURC	613-548-6033	R

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
D4320C00015	A PHASE III, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED ZD4054 10 MG IN NON-METASTATIC HORMONE-RESISTANT PROSTATE CANCER PATIENTS http://www.clinicaltrials.gov/ct2/show/NCT00626548?term=enthuse&rank=2	Astra Zeneca	613-548-6033	R
AZ-CMX-03	A PROSPECTIVE STUDY TO EVALUATE THE INCIDENCE OF SKELETAL RELATED EVENTS IN PROSTATE CANCER PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY (ADT). http://www.clinicaltrials.gov/ct2/show/NCT00632905?term=bhos+CMX&rank=1	CMX Research/ Astra Zeneca	613-549-6666 ext 6787	R
NA	A PROSPECTIVE COHORT STUDY TO EXAMINE THE BIOLOGIC, PSYCHOLOGIC, AND SOCIOLOGIC EFFECTS OF ADT ON QUALITY OF LIFE IN MEN WITH PROSTATE CANCER Link not available	UNK	613-548-6033	R
D6876L00008	AN OPEN-LABEL, PHASE II TRIAL OF MAXIMUM ANDROGEN BLOCKAGE (MAB) DOSE ESCALATION FROM 50 MG TO 150 MG BICALUTAMIDE (CASODEX®) FOR BIOCHEMICAL FAILURE IN PROSTATE CANCER PATIENTS (AGES > 18 YRS) http://www.clinicaltrials.gov/ct/show/NCT00260455?order=1	Astra Zeneca/CURC	Dr. R. Siemens X3848	R
AREN03B2	Renal Tumors Classification, Biology, and Banking Study (Ages 0-29 yrs) Link not available	COG	Dr. M. Silva X3834	R
AREN0321	Treatment of High Risk Renal Tumours (Ages 0-30) http://www.clinicaltrials.gov/ct/show/NCT00335556?order=1	COG	Dr. M. Silva X3834	O

GYNECOLOGICAL TRIALS

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
MKC-103	A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days every 4 Weeks in Patients with Recurrent or Resistant Epithelial Ovarian Cancer or Advanced Endometrial Cancer http://www.clinicaltrials.gov/ct2/show/NCT00607607?term=MKC-103&rank=1	PMH PhII Consortium	Dr. J. Biagi X6736	R
PHL-051	A Phase II Study of VEGF Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00390234?order=13	PMH phII	Dr. J. Biagi X 4184	R
PHL-062	A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma (Ages ≥18 yrs) http://www.clinicaltrials.gov/ct/show/NCT00478426?order=1	PMH PhII Cons	Dr. J. Biagi X 4415	R
HAEMATOLOGICAL TRIALS				
ALC.1	"A phase III study of the addition of gemtuzumab ozogamicin (Mylotarg®) during induction therapy versus standard induction with daunomycin and cytosine arabinoside followed by consolidation and subsequent randomization to post-consolidation therapy with gemtuzumab ozogamicin (Mylotarg®) or no additional therapy for patients under age 56 with previously untreated de novo acute myeloid leukemia (AML)" (Ages 18-55 yrs) http://www.clinicaltrials.gov/ct/show/NCT00085709?order=1	NCIC CTG	Dr. Swain X 4415	R

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
AAML0531	A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults, Down Syndrome Patients (Ages ≥ 4 yrs) http://www.clinicaltrials.gov/ct/show/NCT00372593?order=1	COG	Dr. M. Silva X3834	R
AAML0431	The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Under the Age of 4 Years http://www.clinicaltrials.gov/ct/show/NCT00369317?order=1	COG	Dr. M. Silva X3834	R
ADVL04P2	A Feasibility Pilot and Phase II Study of Chemoimmunotherapy with Epratuzumab for Children with Relapsed CD22- Positive Acute Lymphoblastic Leukemia (Ages 2-31 yrs) http://www.clinicaltrials.gov/ct/show/NCT00098839?order=1	COG	Dr. M. Silva X3834	R
AALL03B1	Classification of Acute Lymphoblastic Leukemia (Ages 0-30 yrs) http://www.clinicaltrials.gov/ct/show/NCT00228722?order=1	COG	Dr. M. Silva X3834	R
AALL05B1	A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens Link not available at this time	COG	Dr. M. Silva X3834	R
AALL0331	Standard Risk B-Precursor ALL (Ages 1-9 yrs) http://www.clinicaltrials.gov/ct/show/NCT00103285?order=1 This trial has been suspended temporarily	COG	Dr. M. Silva X3834	O

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
AALL0232	High Risk B-precursor Acute Lymphoblastic Leukemia (Ages 1-30 yrs) http://www.clinicaltrials.gov/ct/show/NCT00075725?order=1	COG	Dr. M. Silva X3834	R
AALL0433	Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies (Ages 1-29 yrs) http://www.clinicaltrials.gov/ct/show/NCT00381680?order=1 This trial has been suspended temporarily	COG	Dr. M. Silva X3834	O
AALL0434	Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) (Ages 1-30 yrs) http://www.clinicaltrials.gov/ct/show/NCT00408005?order=1 This trial has been suspended temporarily	COG	Dr. M. Silva X3834	O
AALL02P2	Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) Initial CR1 ≥ 18 months (Ages 18months -29 yrs) http://www.clinicaltrials.gov/ct/show/NCT00096135?order=1	COG	Dr. M. Silva X3834	R
AALL03N1	Understanding the Role of Adherence and the Ethnic Differences in Survival After Childhood ALL (Ages 1-21 yrs) http://www.clinicaltrials.gov/ct/show/NCT00268528?order=1	COG	Dr. M. Silva X3834	R

BRAIN TRIALS

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
NA	Evaluation of Biomarkers in Relation to Recurrence Rates in Childhood Ependymoma Link not available yet	C17 Research Network	Dr. M. Silva X3834	R
NA	Weekly Vinblastine for Chemo Naive Children with Pediatric Low Grade Glioma Link not available yet	Hospital for Sick Children (Toronto)	Dr. M. Silva X3834	R
ACNS0331	A Study of Evaluating Limited Target Volume Boost Irradiation and Reduced Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy with Newly Diagnosed Standard Risk Medulloblastoma: A Phase II Double Randomized Study (Ages 3-21 yrs) http://www.clinicaltrials.gov/ct/show/NCT00085735?order=1	COG	Dr. M. Silva X3834	R
ACNS02B1	Pre-Clinical Pharmacology in Surgical Brain Tumour Specimens (Ages 0-21 yrs) Link not available	COG	Dr. M. Silva X3834	R
ACNS02B3	A Children Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens (All ages) http://www.clinicaltrials.gov/ct/show/NCT00228748?order=1	COG	Dr. M. Silva X3834	R
MELANOMA TRIALS				
LYMPHOMA TRIALS				

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
BO20603	RO 4876646-Avastin (bevacizumab), in Combination with Rituxan (rituximab) for the Treatment of CD20-positive Diffuse Large B-cell Lymphoma http://www.clinicaltrials.gov/ct2/show/NCT00486759?term=BO20603&rank=1	ROCHE	Dr. T. Baetz X4415	R
LY12	A phase III study of gemcitabine, dexamethasone, and cisplatin (GDP) compared to dexamethasone, cytarabine, and cisplatin (DHAP) as salvage chemotherapy for patients with relapsed or refractory aggressive histology non-Hodgkin's lymphoma prior to autologous stem cell transplant and followed by maintenance rituximab versus observation (Ages 16-65 yrs) http://www.clinicaltrials.gov/ct/show/NCT00078949?order=3	NCIC CTG	Dr. T. Baetz X4415	R
AHOD0431	Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low-Risk Hodgkin Disease (Ages up to 21 years) http://www.clinicaltrials.gov/ct/show/NCT00302003?order=1	COG	Dr. M. Silva X3834	R
ANHL0131	A Phase III Trial of Treatment of Advanced Stage Anaplastic Large Cell Lymphoma with Standard APO vs. Consolidation with a Regimen Including Vinblastine (Ages 0-20 yrs) http://www.clinicaltrials.gov/ct/show/NCT00059839?order=1	COG	Dr. M. Silva X3834	O

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
AHOD0031	A Phase III Group Wide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin's Disease (Ages 0-21 yrs) http://www.clinicaltrials.gov/ct/show/NCT00025259?order=1	COG	Dr. M. Silva X3834	R
AHOD03P1	Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD) (Ages 0-21 yrs) http://www.clinicaltrials.gov/ct/show/NCT00107198?order=1	COG	Dr. M. Silva X3834	R
AHOD0521	A Phase II Study of Bortezomib (Velcade, PS-341, IND # 58443) in Combination with Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults with Refractory/Recurrent Hodgkin Disease (Ages up to 29 yrs) http://www.clinicaltrials.gov/ct/show/NCT00381940?order=1 This trial has been suspended temporarily	COG	Dr. M. Silva X3834	O
SARCOMA TRIALS				
AEWS07B1	A COG Study for Collecting and Banking Ewing Sarcoma Specimens Link not available yet	COG	Dr. M. Silva X3834	R

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
AEWS07P1	A Pilot Study of Chemotherapy Intensification by Adding Vincristine, Topotecan and Cyclophosphamide to Standard Chemotherapy Agents with an Interval Compression Schedule in Newly Diagnosed Patients with Localized Ewing Sarcoma Family of Tumors (Ages: 0-31 yrs) http://www.clinicaltrials.gov/ct2/show/NCT00618813?term=AEWS07P1&rank=1	COG	Dr. M. Silva X3834	O
D9902	A COG Soft Tissue Sarcoma Biology and Banking Protocol (Ages ≥18yrs) Link not available	COG	Dr. M. Silva X3834	R
AOST06B1	A COG Protocol for Collecting and Banking Osteosarcoma Specimens Link not available yet	COG	Dr. M. Silva X3834	R
AOST0331	Randomized Trial of the European and American Osteosarcoma Study Group to Optimize treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy (Ages 5-40 yrs) http://www.clinicaltrials.gov/ct/show/NCT00134030?order=1	COG	Dr. M. Silva X3834	R
ARST0331	Phase III Study of Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiotherapy in Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma (Ages 0-49 yrs) http://www.clinicaltrials.gov/ct/show/NCT00075582?order=1	COG	Dr. M. Silva X3834	R

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
ARST0332	Risk based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (Ages up to 29 yrs) http://www.clinicaltrials.gov/ct/show/NCT00346164?order=1	COG	Dr. M. Silva X3834	R
ARST0531	Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (Ages up to 50 yrs) http://www.clinicaltrials.gov/ct/show/NCT00354835?order=1	COG	Dr. M. Silva X3834	R
ANBL00B1	Neuroblastoma Biology Study Link not available	COG	Dr. M. Silva X3834	R
ANBLO0P2	Perinatal Neuroblastoma. Expectant Observation (Ages 0-3 months). http://www.clinicaltrials.gov/ct/show/NCT00445718?order=1	COG	Dr. M. Silva X3834	R
ANBL0531	Response and Biology-based Therapy for Intermediate-risk Neuroblastoma (Ages 0-12 yrs) http://www.clinicaltrials.gov/ct2/show/NCT00499616?term=ANBL0531&rank=1	COG	Dr. M. Silva X3834	R
ANBL0532	Phase III Randomized Trial of Single vs. Tandem Myeloablative as Consolidation Therapy for High-Risk Neuroblastoma (Ages up to 30 yrs) http://www.clinicaltrials.gov/ct2/show/NCT00567567?term=ANBL0532&rank=1	COG	Dr. M. Silva X3834	R
UPCOMING TRIALS				

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
CRC5	A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum Link not available yet	NCIC CTG	Dr. C. Booth	P
IND.192	A Phase II Study of Deforolimus in Patients with Metastatic and/or Locally Advanced Recurrent Endometrial Cancer http://www.clinicaltrials.gov/ct2/show/NCT00770185?term=ind+192&rank=1	NCIC CTG	Dr. J. Biagi	P
CLC1 (CALGB 10501)	A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IGVH Unmutated Disease http://clinicaltrials.gov/ct2/show/NCT00513747?term=CALGB+10501&rank=1	NCIC CTG	Dr. G. Swain	P
BO21003	An Open-Label, Dose-Escalating Study to Investigate the Safety and Tolerability of R7159 Monotherapy in Patients With CD20+ Malignant Disease http://clinicaltrials.gov/ct2/show/NCT00576758	Hoffmann-La Roche	Dr. T. Baetz	P

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
EFC6546 (Venice)	A Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of VEGF Trap Versus Placebo Administered every 3 Weeks in Patients Treated with Docetaxel/Prednisone for Metastatic Androgen-Independent Prostate Cancer http://www.clinicaltrials.gov/ct2/show/NCT00519285?term=EFC6546&rank=1	Sanofi Aventis	Dr. R. Gregg	P
PHL-058	Pazopanib With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy http://www.clinicaltrials.gov/ct2/show/NCT00486642?term=PHL-058&rank=1	PMH PhII Cons	Dr. C. Booth	P
PR13	RADICALS Radiotherapy and Androgen Deprivation In Combination After Local Surgery. A randomised controlled trial in prostate cancer http://www.clinicaltrials.gov/ct2/show/NCT00541047?term=PR+13&rank=1	NCIC CTG	Dr. M. Brundage	P
RAPID	Randomized Trial of Accelerated Partial Breast Irradiation (Ages >40 yrs) http://www.clinicaltrials.gov/ct/show/NCT00282035?order=1	OCOG	Dr. C. Falkson X NA	P
A6181170	A Multinational, Randomized, Open-Label, Phase 3 Study of Sunitinib Malate Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma Link not available yet	Pfizer	Dr. J. Biagi X6736	P

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending



Protocol ID(s)	Trial Title	Sponsor(s)	Contact (613) 549-6666	Status
CO20	A Phase III Randomized Study of Brivanib Alaninate (BMS-582664) in Combination with Cetuximab (Erbix) Versus Placebo in Combination with Cetuximab (Erbix) in Patients Previously Treated With Combination Chemotherapy for Metastatic Colorectal Carcinoma http://www.clinicaltrials.gov/ct2/show/NCT00640471?term=co20&rank=1	NCIC CTG	Dr. A. Tomiak X6736	P
CO21	A Phase III Study of The impact of physical activity Program on disease-free survival in patients with early stage colon cancer: a randomized controlled trial (CHALLENGE) Link not available yet	NCIC CTG	Dr. C. Booth X6736	P
OV.18 (ICON6)	A Randomized Trial of Concurrent Cediranib [AZD2171] (with Platinum-Based Chemotherapy) and Maintenance Cediranib in Women with Platinum-Sensitive Relapsed Ovarian Cancer http://www.clinicaltrials.gov/ct2/show/NCT00532194?term=icon6&rank=2	NCIC CTG	Dr. J. Biagi X4415	P
MA31	A Randomized, Open-label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer http://www.clinicaltrials.gov/ct2/show/NCT00667251?term=ma31&rank=1	NCIC CTG	Dr. Y. Madarnas	P

Status Key:

R - Recruiting

P - Pending

O - On Hold

C - Closed on Site

X - Closed by Sponsor

NR - New Recruiting

NP - New Pending